125 related articles for article (PubMed ID: 36812232)
1. Comprehensive analysis of the PTPN13 expression and its clinical implication in breast cancer.
Li JP; Zhang XM; Liu BC; Ren SG; Zhao XH; Liu YJ
Neoplasma; 2023 Apr; 70(2):188-198. PubMed ID: 36812232
[TBL] [Abstract][Full Text] [Related]
2. ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers.
Vermeer PD; Bell M; Lee K; Vermeer DW; Wieking BG; Bilal E; Bhanot G; Drapkin RI; Ganesan S; Klingelhutz AJ; Hendriks WJ; Lee JH
PLoS One; 2012; 7(1):e30447. PubMed ID: 22279592
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of suppressor of cytokine signaling proteins in human breast Cancer.
Sun M; Tang C; Liu J; Jiang W; Yu H; Dong F; Huang C; Rixiati Y
BMC Cancer; 2021 Jun; 21(1):696. PubMed ID: 34120621
[TBL] [Abstract][Full Text] [Related]
4. Tumor mutation burden and
Zhang X; Li J; Yang Q; Wang Y; Li X; Liu Y; Shan B
Ann Transl Med; 2020 Sep; 8(17):1052. PubMed ID: 33145271
[TBL] [Abstract][Full Text] [Related]
5. Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance.
Zhan H; Jiang J; Luo C; Sun Q; Ke A; Sun C; Hu J; Hu Z; Hu B; Zhu K; Fan J; Zhou J; Huang X
Tumour Biol; 2016 Jul; 37(7):9691-8. PubMed ID: 26801674
[TBL] [Abstract][Full Text] [Related]
6. The nonreceptor-type tyrosine phosphatase PTPN13 is a tumor suppressor gene in non-small cell lung cancer.
Scrima M; De Marco C; De Vita F; Fabiani F; Franco R; Pirozzi G; Rocco G; Malanga D; Viglietto G
Am J Pathol; 2012 Mar; 180(3):1202-1214. PubMed ID: 22245727
[TBL] [Abstract][Full Text] [Related]
7. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
8. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
[TBL] [Abstract][Full Text] [Related]
9. The expression landscape of FOXP3 and its prognostic value in breast cancer.
Li J; Zhang X; Liu B; Shi C; Ma X; Ren S; Zhao X; Liu Y
Ann Transl Med; 2022 Jul; 10(14):801. PubMed ID: 35965804
[TBL] [Abstract][Full Text] [Related]
10. High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
Fan L; Sui XY; Jin X; Zhang WJ; Zhou P; Shao ZM
BMC Cancer; 2023 Apr; 23(1):298. PubMed ID: 37005579
[TBL] [Abstract][Full Text] [Related]
11. Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer.
Chen C; Gao D; Huo J; Qu R; Guo Y; Hu X; Luo L
Sci Rep; 2021 Jun; 11(1):12172. PubMed ID: 34108519
[TBL] [Abstract][Full Text] [Related]
12. Dual Role of the PTPN13 Tyrosine Phosphatase in Cancer.
Mcheik S; Aptecar L; Coopman P; D'Hondt V; Freiss G
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33322542
[TBL] [Abstract][Full Text] [Related]
13. PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
Long Q; Sun J; Lv J; Liang Y; Li H; Li X
Exp Cell Res; 2020 Nov; 396(1):112286. PubMed ID: 32919955
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
Jiang T; Shi W; Wali VB; Pongor LS; Li C; Lau R; Győrffy B; Lifton RP; Symmans WF; Pusztai L; Hatzis C
PLoS Med; 2016 Dec; 13(12):e1002193. PubMed ID: 27959926
[TBL] [Abstract][Full Text] [Related]
15. Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.
Gao C; Li H; Liu C; Xu X; Zhuang J; Zhou C; Liu L; Feng F; Sun C
Front Immunol; 2021; 12():650491. PubMed ID: 33968045
[TBL] [Abstract][Full Text] [Related]
16. Genomic Profiling Comparison of Germline
Huang X; Shao D; Wu H; Zhu C; Guo D; Zhou Y; Chen C; Lin Y; Lu T; Zhao B; Wang C; Sun Q
Front Oncol; 2020; 10():583314. PubMed ID: 33194720
[No Abstract] [Full Text] [Related]
17. PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness.
Hamyeh M; Bernex F; Larive RM; Naldi A; Urbach S; Simony-Lafontaine J; Puech C; Bakhache W; Solassol J; Coopman PJ; Hendriks WJAJ; Freiss G
Theranostics; 2020; 10(3):1016-1032. PubMed ID: 31938048
[TBL] [Abstract][Full Text] [Related]
18. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
Erturk E; Cecener G; Tezcan G; Egeli U; Tunca B; Gokgoz S; Tolunay S; Tasdelen I
Gene; 2015 Feb; 556(2):163-9. PubMed ID: 25445393
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
[TBL] [Abstract][Full Text] [Related]
20. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
